<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="d32e1168">
  <p id="ntpara0010">
   <bold>The Thematic Reviews on Vaccines will continue in an upcoming issue.</bold>
  </p>
 </fn>
 <fn id="d32e1171">
  <p id="ntpara0015">
   <bold>Potential Competing Interests:</bold> Dr Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories and is a consultant on vaccine development to Merck &amp; Co. Inc, Avianax LLC, Adjuvance, Valneva SE, Medicago Inc, Sanofi Pasteur Limited, GlaxoSmithKline plc, and Emergent BioSolutions Inc. Drs Poland and Ovsyannikova hold 3 patents related to vaccinia and measles peptide vaccines. Dr Kennedy holds a patent related to vaccinia peptide vaccines and has received funding from 
   <funding-source id="gs1">Merck Research Laboratories</funding-source> to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
  </p>
 </fn>
</fn-group>
